Stockreport

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

Werewolf Therapeutics, Inc.  (HOWL) 
PDF CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of c [Read more]